-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
A project of Shijiazhuang Fourth Pharmaceutical has won the third prize of the Shijiazhuang High-Tech Achievement Implementation Award.
Category:
Time：2023-05-11
To accelerate the commercialization and implementation of high-tech achievements and promote the rapid development of our city’s high-tech industry, in accordance with the “Measures for Rewarding the Implementation of High-Tech Achievements in Shijiazhuang,” the municipal government has decided to award units that have made outstanding contributions to the construction of high-tech industrialization projects and the commercialization of high-tech achievements in 2022. The project “Industrialization of Basic Solution for Hemofiltration and Hemodiafiltration” by Shijiazhuang Sihua Pharmaceutical Co., Ltd. has been awarded the Third Prize of the Shijiazhuang High-Tech Achievement Implementation Award.
To accelerate the commercialization and implementation of high-tech achievements and promote the rapid development of our city’s high-tech industry, in accordance with the “Measures for Rewarding the Implementation of High-Tech Achievements in Shijiazhuang,” the municipal government has decided to award units that have made outstanding contributions to the construction of high-tech industrialization projects and the commercialization of high-tech achievements in 2022. The project “Industrialization of Basic Solution for Hemofiltration and Hemodiafiltration” undertaken by Shijiazhuang Sihua Pharmaceutical Co., Ltd. has been awarded the Third Prize of the Shijiazhuang High-Tech Achievement Implementation Award.
The “Industrialization of Hemofiltration Replacement Base Solution” project is built upon the key technologies developed under the company’s first-prize-winning project, “Establishment and Application of a Quality Control System for Soft-Packaged Large Volume Infusions,” which earned the Hebei Province Science and Technology Progress Award. The project utilizes three key technology patents. As one of only three companies in China approved to produce hemofiltration replacement base solutions, Shijiazhuang Fourth Pharmaceutical has independently innovated and developed this product, completing process validation, quality standard research, and stability testing for the hemofiltration replacement base solution. By precisely controlling critical process steps and parameters, the product quality meets the drug registration standards set by the National Medical Products Administration, and the process technology has reached a domestically leading level.
It is understood that the prescription for the blood filtration replacement base solution does not contain potassium ions or lactate, making it more suitable as a base replacement fluid and effectively reducing the burden on the liver.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license